GT Biopharma has received FDA clearance for its IND application for GTB-5550, a novel B7-H3-targeted TriKE therapy for multiple myeloma, allowing it to proceed with human trials. This marks a significant step in the drug's development, potentially offering a new treatment option for a rare blood cancer, contingent on securing non-dilutive grant funding.
GT Biopharma announced FDA IND clearance for its multiple myeloma drug, GTB-5550, enabling the initiation of Phase 1a/1b human trials. This is a crucial de-risking event for the company, as it validates the drug's potential and allows for clinical progression. The news is positive for GTBP in the short term, as evidenced by premarket trading, and offers long-term opportunity if the trials are successful. However, the trial initiation is contingent on securing non-dilutive grant funding, which introduces a potential delay or risk if not obtained.